# Desmoid Tumors & Fibromatosis — GCMD Library living collection

Updated: n/a · 8 episodes · 65 cited statements

## Episodes
### Interventional Therapy
- ["Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978) — video · 9:32 · [machine version](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978.md)

### Medical Management
- [Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors](https://library.globalcastmd.com/article/nirogacestat-a-secretase-inhibitor-for-desmoid-tumors-17005) — article · [machine version](https://library.globalcastmd.com/article/nirogacestat-a-secretase-inhibitor-for-desmoid-tumors-17005.md)
- [Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors](https://library.globalcastmd.com/article/retrospective-case-series-highlighting-the-real-world-experience-of-nirogacestat-17000) — article · [machine version](https://library.globalcastmd.com/article/retrospective-case-series-highlighting-the-real-world-experience-of-nirogacestat-17000.md)
- [Pazopanib therapy for desmoid tumors in adolescent and young adult patients](https://library.globalcastmd.com/article/pazopanib-therapy-for-desmoid-tumors-in-adolescent-and-young-adult-patients-17026) — article · [machine version](https://library.globalcastmd.com/article/pazopanib-therapy-for-desmoid-tumors-in-adolescent-and-young-adult-patients-17026.md)

### Related Fibroproliferative Disorders
- [Single institution series of nodular fasciitis in children](https://library.globalcastmd.com/article/single-institution-series-of-nodular-fasciitis-in-children-17045) — article · [machine version](https://library.globalcastmd.com/article/single-institution-series-of-nodular-fasciitis-in-children-17045.md)
- [Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations](https://library.globalcastmd.com/article/solitary-myofibroma-preceding-the-development-of-multicentric-myofibromatosis-a-17020) — article · [machine version](https://library.globalcastmd.com/article/solitary-myofibroma-preceding-the-development-of-multicentric-myofibromatosis-a-17020.md)
- [Reply to comment on: Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations.](https://library.globalcastmd.com/article/reply-to-comment-on-solitary-myofibroma-preceding-the-development-of-multicentri-17018) — article · [machine version](https://library.globalcastmd.com/article/reply-to-comment-on-solitary-myofibroma-preceding-the-development-of-multicentri-17018.md)
- [Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex](https://library.globalcastmd.com/article/sirolimus-therapy-for-fibromatosis-and-multifocal-renal-cell-carcinoma-in-a-chil-17046) — article · [machine version](https://library.globalcastmd.com/article/sirolimus-therapy-for-fibromatosis-and-multifocal-renal-cell-carcinoma-in-a-chil-17046.md)

## Chapters
- [0:17](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=17) Introduction and rationale for combining cryoablation with medical therapy (Ep 1)
- [2:27](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=147) Cryoablation technique and Cincinnati Children's approach (Ep 1)
- [4:06](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=246) Patient cohort characteristics and outcomes (Ep 1)
- [5:58](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=358) Case examples of exceptional outcomes (Ep 1)
- [7:27](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=447) Summary and proposed treatment model (Ep 1)

## Statements
Every statement is attributed, typed, and timestamped; the link is the citation.
- At Cincinnati Children's Hospital, gamma secretase inhibitors are considered standard of care for patients requiring medical therapy, especially young adults and older adolescent pediatric patients. — Joseph G. Pressey (clinical) [Ep 1 · 1:00](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=60)
- Cryoablation is an interventional radiology ablative procedure that uses argon gas to create an ice ball. — Joseph G. Pressey (clinical) [Ep 1 · 2:35](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=155)
- One to three probes are typically used for cryoablation depending on the size and shape of the tumor. — Joseph G. Pressey (clinical) [Ep 1 · 2:51](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=171)
- The tumor is frozen down to minus 140 to minus 190 degrees Fahrenheit during cryoablation, forming an ice ball around part or all of the tumor. — Joseph G. Pressey (clinical) [Ep 1 · 3:03](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=183)
- Cincinnati Children's Hospital has been offering cryoablation for desmoid tumors since 2021. — Joseph G. Pressey (clinical) [Ep 1 · 3:20](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=200)
- Cincinnati Children's uses a standard two-cycle freeze-thaw approach to cryoablation. — Joseph G. Pressey (clinical) [Ep 1 · 3:31](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=211)
- Nerve monitoring is performed when vital nerves run near the tumor, and skin warming is used to prevent necrosis of overlying skin. — Joseph G. Pressey (clinical) [Ep 1 · 3:39](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=219)
- Patients are under general anesthesia during cryoablation and typically admitted to the hospital afterwards for pain control, usually overnight but up to three days depending on location and treatment plan. — Joseph G. Pressey (clinical) [Ep 1 · 3:48](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=228)
- Cryoablation procedures are often ultrasound or CT guided. — Joseph G. Pressey (clinical) [Ep 1 · 4:03](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=243)
- Cincinnati Children's has treated 14 patients with 25 technically successful cryoablation procedures for desmoid tumors. — Joseph G. Pressey (epidemiological) [Ep 1 · 4:06](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=246)
- The patient cohort ranged from 8 to 43 years of age with a median age of 20 years. — Joseph G. Pressey (epidemiological) [Ep 1 · 4:15](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=255)
- Patients required one to three probes during therapy and had anywhere from one to four procedures depending on tumor size and shape. — Joseph G. Pressey (epidemiological) [Ep 1 · 4:22](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=262)
- Some tumors got larger after cryoablation while others dramatically shrunk in size. — Joseph G. Pressey (clinical) [Ep 1 · 4:30](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=270)
- Tumors that decreased in size also showed decreased T2 hyperintensity on MRI. — Joseph G. Pressey (clinical) [Ep 1 · 4:43](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=283)
- At 12 months after cryoablation, 86% of patients had not started a new medical therapy. — Joseph G. Pressey (epidemiological) [Ep 1 · 5:36](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=336)
- At 36 months after cryoablation, 55% of patients had not started a new medical therapy. — Joseph G. Pressey (epidemiological) [Ep 1 · 5:36](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=336)
- The patient cohort was heterogeneous and many had been heavily pre-treated. — Joseph G. Pressey (epidemiological) [Ep 1 · 5:42](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=342)
- Pazopanib is very much like sorafenib, cousins in effect. — Joseph G. Pressey (clinical) [Ep 1 · 6:10](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=370)
- Nine out of 13 patients reported improved pain after cryoablation. — Joseph G. Pressey (epidemiological) [Ep 1 · 7:34](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=454)
- Six out of 11 patients reported improved function after cryoablation. — Joseph G. Pressey (epidemiological) [Ep 1 · 7:34](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=454)
- There were no grade 3 or grade 4 toxicities from cryoablation in this cohort. — Joseph G. Pressey (clinical) [Ep 1 · 7:41](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=461)
- Cincinnati Children's has taken a modest approach where 30 to 90% of the tumor is frozen, not attempting to freeze the entire tumor unless very easy to do. — Joseph G. Pressey (clinical) [Ep 1 · 7:44](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=464)
- Subtotal cryoablation was found to be effective and safe. — Joseph G. Pressey (clinical) [Ep 1 · 8:11](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=491)
- Approximately half of the patients did not require subsequent new medical therapy after undergoing cryoablation. — Joseph G. Pressey (epidemiological) [Ep 1 · 8:18](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=498)
- Many patients had received medical therapy up until the point where they underwent cryoablation. — Joseph G. Pressey (epidemiological) [Ep 1 · 8:26](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=506)
- There appear to be no overlapping toxicities between prior medical therapy and subsequent cryoablation. — Joseph G. Pressey (clinical) [Ep 1 · 8:33](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=513)
- Desmoid tumors have a peak incidence in young adulthood and often cause pain, loss of function, and diminished quality of life. (established) (no timestamp yet)
- Nirogacestat, a selective gamma secretase inhibitor, was approved by the US Food and Drug Administration in November 2023 for the treatment of patients with desmoid tumors based on findings from the Phase III DeFi trial. (established) (no timestamp yet)
- The median patient age in this series was 26 years. (research) (no timestamp yet)
- The median duration of nirogacestat therapy at the time of the study was 8 months. (research) (no timestamp yet)
- RECIST responses included one patient with a partial response, eight with stable disease, and two were deemed radiologically inevaluable. (research) (no timestamp yet)
- Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in MRI T2-weighted signal intensity. (research) (no timestamp yet)
- Nine out of 10 patients who presented with pain (90%) reported rapid improvement. (research) (no timestamp yet)
- The most common toxicities of nirogacestat included diarrhea, nausea, rash, and ovarian dysfunction. (research) (no timestamp yet)
- Discontinuation of nirogacestat was necessary in one patient due to severe diarrhea. (research) (no timestamp yet)
- Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. (established) (no timestamp yet)
- Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat at 150 mg or placebo twice daily. (recommendation) (no timestamp yet)
- Nirogacestat had a significant progression-free survival benefit over placebo with a hazard ratio for disease progression or death of 0.29 (95% confidence interval, 0.15 to 0.55; P<0.001). (research) (no timestamp yet)
- The likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo. (research) (no timestamp yet)
- The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41% vs. 8%; P<0.001). (research) (no timestamp yet)
- The median time to response was 5.6 months with nirogacestat and 11.1 months with placebo. (research) (no timestamp yet)
- The percentage of patients with a complete response was 7% with nirogacestat and 0% with placebo. (research) (no timestamp yet)
- Significant between-group differences were observed in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life. (research) (no timestamp yet)
- Infantile myofibroma is the most common fibrous tumor of infancy. (established) (no timestamp yet)
- Solitary myofibromas can progress to diffuse myofibromatosis. (research) (no timestamp yet)
- Morbidity and potential mortality vary based on the extent of myofibromatosis disease. (established) (no timestamp yet)
- Surgical resection of desmoid tumors had a 68% recurrence rate in this cohort. (research) (no timestamp yet)
- Of eight patients who received vinblastine/methotrexate, only one had a partial response by RECIST 1.1 and five had stable disease. (research) (no timestamp yet)
- 62.5% of patients treated with vinblastine/methotrexate required additional therapy. (research) (no timestamp yet)
- Of seven patients who received sulindac/tamoxifen, none showed objective improvement. (research) (no timestamp yet)
- Pazopanib demonstrated best responses by RECIST of partial response in two of seven and stable disease in six of seven tumors. (research) (no timestamp yet)
- A partial response of 66% was observed with pazopanib in a patient who had failed multiple prior therapies. (research) (no timestamp yet)
- Mesenteric desmoid tumor showed partial response to pazopanib. (research) (no timestamp yet)
- Maximum volumetric decrease by T2-weighted MRI with pazopanib therapy was 97%. (research) (no timestamp yet)
- Nodular fasciitis often resembles malignant sarcomas from a clinical and pathologic perspective. (established) (no timestamp yet)
- A case series of 18 nodular fasciitis cases at Children's Hospital of Alabama between 1997 and 2009 showed a male predominance. (research) (no timestamp yet)
- Nodular fasciitis in this series showed a predilection for the head and neck. (research) (no timestamp yet)
- All 18 nodular fasciitis cases underwent surgical excision. (research) (no timestamp yet)
- Only one tumor recurred after the initial surgical intervention in this series of 18 cases. (research) (no timestamp yet)
- All patients with nodular fasciitis in this series ultimately recovered with minimal morbidity. (research) (no timestamp yet)
- A male patient with tuberous sclerosis complex developed chest wall fibromatosis and bilateral multifocal renal cell carcinoma. (established) (no timestamp yet)
- The fibromatosis tumor recurred 5 years after initial resection during infancy. (research) (no timestamp yet)
- The more extensively affected right kidney was resected due to bilateral renal cell carcinoma. (research) (no timestamp yet)
- Sirolimus was used to avoid bilateral nephrectomies in this patient. (recommendation) (no timestamp yet)
- Within 6 months of sirolimus therapy, the fibromatosis and remaining renal cell carcinoma tumors responded substantially with minimal adverse effects. (research) (no timestamp yet)

## Host summaries
Recaps by a host of what the experts said — not the host's own clinical position.
- Nirogastat and presumably other gamma secretase inhibitors work well for desmoid tumors based on published DeFi study data. — Joseph G. Pressey summarizing a resource [Ep 1 · 0:46](https://library.globalcastmd.com/watch/subtotal-percutaneous-cryoablation-for-extra-abdominal-desmoid-tumors-with-josep-16978?t=46)

---
Educational content from recorded physician discussions — not medical advice. Cite the canonical URL or the ?t= deep link. Policy: https://library.globalcastmd.com/ai
